Multiple sclerosis (Houndmills, Basingstoke, England)最新文献_第6页

Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis. 血浆胶质原纤维酸性蛋白和神经丝轻链与多发性硬化症残疾恶化的关系。

IF 5.8

Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-10-01 Epub Date: 2022-05-21 DOI: 10.1177/13524585221094224

Ayla Pauwels, Jeroen Van Schependom, Lindsay Devolder, Ann Van Remoortel, Guy Nagels, Maria Bjerke, Marie B D'hooghe

{"title":"Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.","authors":"Ayla Pauwels, Jeroen Van Schependom, Lindsay Devolder, Ann Van Remoortel, Guy Nagels, Maria Bjerke, Marie B D'hooghe","doi":"10.1177/13524585221094224","DOIUrl":"https://doi.org/10.1177/13524585221094224","url":null,"abstract":"Background: Predicting disability worsening in multiple sclerosis (MS) remains an important challenge. Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) seem promising biomarkers. Studies investigating blood GFAP in relation to longitudinal outcome measures in MS are scarce.Objective: To compare plasma-GFAP (p-GFAP) and plasma-NfL (p-NfL) levels in relation to sustained disability worsening.Methods: We measured baseline p-GFAP and p-NfL in a prospective cohort of 115 individuals with MS and 30 matched controls, using Single Molecule Array (Simoa). Disability worsening was defined as an increase in at least one of three measures (Expanded Disability Status Scale, Timed 25-foot walk, 9-Hole Peg test), confirmed after 6 months and persistent upon data closure.Results: In a multivariable Cox proportional-hazards model, p-GFAP was not significantly associated with sustained disability worsening after 4.40 ± 0.82 years, while p-NfL (HR = 1.046, p = 0.001), EDSS (HR = 1.24, p = 0.039), and disease duration (HR = 1.048, p = 0.017) were. Area under the curve of ROC curves in relation to worsening was 0.61 for p-GFAP (p = 0.031) and 0.63 for p-NfL (p = 0.015). Kaplan-Meier curves showed similar patterns for both proteins.Conclusion: p-NfL emerged as a significant explanatory variable for worsening in Cox regression analysis, and p-GFAP did not. Both p-GFAP and p-NfL were related to worsening based on ROC curves.","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1685-1696"},"PeriodicalIF":5.8,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40348729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

All anti-CD20 monoclonal antibodies have similar efficacy and risks: Commentary. 所有抗cd20单克隆抗体具有相似的疗效和风险:评论。

IF 5.8

Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-10-01 DOI: 10.1177/13524585221122219

Ian Dimaandal, Jaime Imitola

引用次数: 0

Grey-matter sodium concentration as an individual marker of multiple sclerosis severity. 灰质钠浓度作为多发性硬化症严重程度的个体标志物。

IF 5.8

Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-10-01 Epub Date: 2022-06-20 DOI: 10.1177/13524585221102587

Adil Maarouf, Bertrand Audoin, Soraya Gherib, Mohamed Mounir El Mendili, Patrick Viout, Fanelly Pariollaud, Clémence Boutière, Audrey Rico, Maxime Guye, Jean-Philippe Ranjeva, Wafaa Zaaraoui, Jean Pelletier

{"title":"Grey-matter sodium concentration as an individual marker of multiple sclerosis severity.","authors":"Adil Maarouf, Bertrand Audoin, Soraya Gherib, Mohamed Mounir El Mendili, Patrick Viout, Fanelly Pariollaud, Clémence Boutière, Audrey Rico, Maxime Guye, Jean-Philippe Ranjeva, Wafaa Zaaraoui, Jean Pelletier","doi":"10.1177/13524585221102587","DOIUrl":"https://doi.org/10.1177/13524585221102587","url":null,"abstract":"Objective: Quantification of brain injury in patients with variable disability despite similar disease duration may be relevant to identify the mechanisms underlying disability in multiple sclerosis (MS). We aimed to compare grey-matter sodium abnormalities (GMSAs), a parameter reflecting neuronal and astrocyte dysfunction, in MS patients with benign multiple sclerosis (BMS) and non-benign multiple sclerosis (NBMS). Methods: We identified never-treated BMS patients in our local MS database of 1352 patients. A group with NBMS was identified with same disease duration. All participants underwent 23Na magnetic resonance imaging (MRI). The existence of GMSA was detected by statistical analysis. Results: In total, 102 individuals were included (21 BMS, 25 NBMS and 56 controls). GMSA was detected in 10 BMS and 19 NBMS (11/16 relapsing-remitting multiple sclerosis (RRMS) and 8/9 secondary progressive multiple sclerosis (SPMS) patients) (p = 0.05). On logistic regression including the presence or absence of GMSA, thalamic volume, cortical grey-matter volume and T2-weighted lesion load, thalamic volume was independently associated with BMS status (odds ratio (OR) = 0.64 for each unit). Nonetheless, the absence of GMSA was independently associated when excluding patients with significant cognitive alteration (n = 7) from the BMS group (OR = 4.6). Conclusion: Detection of GMSA in individuals and thalamic volume are promising to differentiate BMS from NBMS as compared with cortical or whole grey-matter atrophy and T2-weighted lesions.","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1903-1912"},"PeriodicalIF":5.8,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40058299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The value of patient-reported outcome measures for multiple sclerosis. 多发性硬化症患者报告结果测量的价值。

IF 5.8

Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-09-01 DOI: 10.1177/13524585221111675

Marisa P McGinley, Brittany Lapin

引用次数: 3

Serum neurofilament light in MS: The first true blood-based biomarker? 多发性硬化症患者血清神经丝光:首个真正的血液生物标志物?

IF 5.8

Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-09-01 Epub Date: 2021-02-10 DOI: 10.1177/1352458521993066

Simon Thebault, Gauruv Bose, Ronald Booth, Mark S Freedman

{"title":"Serum neurofilament light in MS: The first true blood-based biomarker?","authors":"Simon Thebault, Gauruv Bose, Ronald Booth, Mark S Freedman","doi":"10.1177/1352458521993066","DOIUrl":"https://doi.org/10.1177/1352458521993066","url":null,"abstract":"A simple blood-derived biomarker is desirable in the routine management of multiple sclerosis (MS) patients and serum neurofilament light chain (sNfL) is the most promising candidate. Although its utility was first shown in cerebrospinal fluid (CSF), technological advancements have enabled reliable detection in serum and less frequently plasma, obviating the need for repeated lumbar punctures. In this review, after defining the knowledge gap in MS management that many hope sNfL could fill, we summarize salient studies demonstrating associations of sNfL levels with outcomes of interest. We group these outcomes into inflammatory activity, progression, treatment response, and prediction/prognosis. Where possible we focus on data from real-world perspective observational cohorts. While acknowledging the limitations of sNfL and highlighting key areas for ongoing work, we conclude with our opinion of the role for sNfL as an objective, convenient, and cost-effective adjunct to clinical assessment. Paving the way for other promising biomarkers both blood-derived and otherwise, sNfL is an incremental step toward precision medicine for MS patients.","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1491-1497"},"PeriodicalIF":5.8,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1352458521993066","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25355177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 26

The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. MSIS-29和SF-36作为继发性进展性MS试验的结局。

IF 5.8

Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-09-01 DOI: 10.1177/13524585221105465

Eva Mm Strijbis, Pavle Repovic, Jop Mostert, James D Bowen, Bernard Mj Uitdehaag, Gary Cutter, Marcus W Koch

{"title":"The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.","authors":"Eva Mm Strijbis, Pavle Repovic, Jop Mostert, James D Bowen, Bernard Mj Uitdehaag, Gary Cutter, Marcus W Koch","doi":"10.1177/13524585221105465","DOIUrl":"https://doi.org/10.1177/13524585221105465","url":null,"abstract":"Background: Patient-reported outcome measures (PROMs) are often used in clinical research, but little is known about their performance as longitudinal outcomes.Methods: We used data from ASCEND, a large SPMS trial (n = 889), to investigate changes on the Short Form Health Survey 36 (SF-36 v2) and the Multiple Sclerosis Impact Scale (MSIS-29) over 2 years of follow-up.Results: PROM scores changed little over the 2 years of follow-up. In contrast to physical disability measures, there was no consistent trend in PROM change: significant worsening occurred about as often as improvement. Using a 6-month confirmation reduced the number of both worsening and improvement events without altering their relative balance. There was no clear difference in worsening events in groups based on population characteristics, nor was there a noticeable effect using different thresholds for clinically significant change.Conclusion: We found little consistent change in MSIS-29 and SF-36 over 2 years of follow-up in people with SPMS. Our findings show a disconnect between disability worsening and PROM change in this population. Our findings raise caution about the use of these PROMs as primary outcome measures in SPMS trials and call for a critical reappraisal of the longitudinal use of these measures in SPMS trials.","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1606-1619"},"PeriodicalIF":5.8,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40551907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

It is imperative to reconsider the concept of seronegative NMOSD. 必须重新考虑血清阴性NMOSD的概念。

IF 5.8

Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-09-01 DOI: 10.1177/13524585221111057

Romain Marignier

引用次数: 1

Therapy with mesenchymal stem cell transplantation in multiple sclerosis ready for prime time: Commentary. 间充质干细胞移植治疗多发性硬化症已准备就绪:评论。

IF 5.8

Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-08-01 DOI: 10.1177/13524585221097958

Luca Peruzzotti-Jametti, Stefano Pluchino

引用次数: 2

Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES. 间充质干细胞移植治疗多发性硬化症的时机已经成熟:是的。

IF 5.8

Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-08-01 DOI: 10.1177/13524585211062173

Dimitrios Karussis, Ibrahim Kassis, Panayiota Petrou

引用次数: 0

Progressive myelin oligodendrocyte glycoprotein-associated demyelination mimicking leukodystrophy. 进行性髓鞘少突胶质细胞糖蛋白相关脱髓鞘模拟白质营养不良。

IF 5.8

Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-08-01 Epub Date: 2022-06-23 DOI: 10.1177/13524585221090737

Emily Gibbons, Daniel Whittam, Kariem Elhadd, Maneesh Bhojak, Nitika Rathi, Shivaram Avula, Anu Jacob, Michael Griffiths, Saif Huda

{"title":"Progressive myelin oligodendrocyte glycoprotein-associated demyelination mimicking leukodystrophy.","authors":"Emily Gibbons, Daniel Whittam, Kariem Elhadd, Maneesh Bhojak, Nitika Rathi, Shivaram Avula, Anu Jacob, Michael Griffiths, Saif Huda","doi":"10.1177/13524585221090737","DOIUrl":"https://doi.org/10.1177/13524585221090737","url":null,"abstract":"Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) may be associated with relapsing disease, but clinical progression independent of relapse activity is rare.Objectives: To report progressive disease in a patient with MOGAD.Methods: A single retrospective case report.Results: At 4 years of age, the patient had a single episode of acute disseminated encephalomyelitis. She remained well until age 17 years but over the next 9 years developed progressive spastic quadriparesis, cognitive and bulbar dysfunction. Brain imaging showed a leukodystrophy-like pattern of white matter abnormality with contrast enhancement at different time points. Myelin oligodendrocyte glycoprotein (MOG)-IgG was repeatedly positive by live cell-based assay.Conclusion: Secondary progression may be a rare presentation of MOG-IgG-associated disease.","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1481-1484"},"PeriodicalIF":5.8,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40240576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0